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ekey role of dyslipidaemia in determining cardiovascular disease (CVD)has been proved beyond reasonable doubt, and therefore
several dietary and pharmacological approaches have been developed. e discovery of statins has provided a very eﬀective
approach in reducing cardiovascular risk as documented by the results obtained in clinical trials and in clinical practice.e current
eﬃcacy of statins or other drugs, however, comes short of providing the beneĕt that could derive from a further reduction of LDL
cholesterol (LDL-C) in high-risk and very high risk patients. Furthermore, experimental data clearly suggest that other lipoprotein
classes beyond LDL play important roles in determining cardiovascular risk. For these reasons a number of new potential drugs
are under development in this area. Aim of this review is to discuss the available and the future pharmacological strategies for the
management of dyslipidemia.
1. Dyslipidaemia and Atherosclerosis
Atherosclerosis is a multifactorial disease in which plaque
formation is the ĕnal process for several common patho-
genetic mechanisms, including the individual susceptibility
of genetic origin, hemodynamic stress, and various combina-
tions of risk factors such as hypercholesterolemia, hyperten-
sion, diabetes, immune reactions and autoimmune diseases,
inĘammation, viral infections, and cigarette smoking [1–3].
e initiating event in atherosclerosis is the subendothe-
lial retention of apolipoprotein apoB-containing lipoproteins
in the arterial wall. is process is strictly related to the
plasma levels of apoB-lipoproteins, however other properties
can inĘuence it, including lipoprotein size, charge and com-
position, and endothelial permeability. Very large lipopro-
tein (nonhydrolyzed chylomicrons) cannot enter the arterial
wall, thus they do not directly promote atherosclerosis [4];
remnant chylomicrons, that are smaller, can enter the arterial
wall, and can be retained [5]. LDL, which is the major
cholesterol carrier in human plasma, has a key role in the
initiation of the atherosclerotic process as conĕrmed by the
great eﬃcacy of LDL-lowering therapies in the prevention
of cardiovascular disease [6–8]. Several factors may aﬀect
the endothelial permeability to lipoproteins, including the
extent of the atherosclerotic lesion [9] and damages of the
arterial wall. LDL concentration at the luminal surface may
increase in areas where blood Ęow and shear stress are low
and where the permeability of the endothelial layer is higher,
thus increasing the entry of LDL in the intima in these sites
[10].
e deposition and modiĕcation of LDL in the arterial
wall promote a number of key processes including (1) impair-
ment of endothelial function, (2) invasion of the arterial wall
by leukocytes, particularlymonocytes andT lymphocytes, (3)
internalization of lipoproteins in macrophages and smooth
muscle cells and accumulation of lipids, and (4) phenotypic
modulation and proliferation of smooth muscle cells and
synthesis of extracellular matrix.
Atherosclerotic lesions develop primarily in large and
medium arteries, and above all in the intima, that is, the
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innermost layer of the arterial wall, consisting of a monolayer
of endothelial cells adherent to a thin layer of connective tis-
sue.e intima is separated from the tunicamedia, consisting
of smoothmuscle cells, collagen, and glycosaminoglycans, by
the internal elastic lamina.
e evolution of the atherosclerotic lesion is character-
ized by three stages [2].
(1) Fatty streak formation [11]: the process begins with
the accumulation of LDL (low-density lipoprotein)
in the subendothelial space of the artery wall, where
they interact speciĕcally with components of the
extracellular matrix [12, 13] and undergo several
modiĕcations (oxidation, glycation, aggregation, or
formation of immune complexes) [14, 15], thus
inducing endothelial cell activation. Following oxida-
tion, the LDL is internalized bymacrophages (derived
from circulating monocytes recruited in the suben-
dothelial space by chemokines produced by the acti-
vated endothelium), with subsequent accumulation
of intracellular lipids and the formation of “foam
cells”.
(2) Fibrous plaque formation: at this stage the lesion is
enriched in macrophages and proliferating smooth
muscle cells; moreover, the formation of connective
tissue and intracellular and extracellular accumula-
tion of lipids are characteristic of this step.
(3) Complicated lesions are the most advanced form of
ĕbrous plaques. An important feature of complicated
lesions is the formation of a lipid core, whose dimen-
sions are related to the stability of atherosclerotic
plaque [16].e extracellular lipids are derived either
from an increased inĘux of lipids not neutralised by
internalization or removal by the cells, and from dead
cells.e phenomenon of cell death, which can occur
either by apoptosis or necrosis [17], is then related to
the physical possibility of a rupture of the plaque, with
consequent problems of coronary thrombosis.
2. Established Approaches for the Management
of Dyslipidaemia
e key role of dyslipidaemias in determining cardiovas-
cular disease (CVD) has been proved beyond reasonable
doubt, and therefore several dietary and pharmacologi-
cal approaches are used in the clinical practice for the
management of dyslipidemia (Table 1) [18]. ese include
molecules and nutraceuticals which inĘuence the absorp-
tion of dietary cholesterol or the synthesis of endogenous
cholesterol, impact triglyceride and/or fatty acid handling, or
increase HDL levels.
2.1. Dietary Supplements and Functional Foods. ere are
many functional foods and dietary supplements that are cur-
rently promoted as beneĕcial for people with dyslipidaemia
or for reducing the risk of CVD. Some of these products have
been shown to have potentially relevant functional eﬀects
but have not been tested in long-term clinical trials and
should therefore be utilized only when the available evidence
clearly supports their beneĕcial eﬀects on plasma lipid values
and their safety. Based on the available evidence, foods
enriched with phytosterols (1-2 g/day) may be considered for
individuals with elevated TC and LDL-C values in whom
the total CV risk assessment does not justify the use of
cholesterol-lowering drugs [19].
2.2. Bile Acid Sequestrants. Bile acid sequestrants are anion
exchange resins that bind bile acids in the gastrointestinal
tract. Bile acids are synthesized in the liver from cholesterol
and released into the intestinal lumen; however most of the
bile acid is returned to the liver from the terminal ileum via
active absorption. e bile acid sequestrants are not system-
ically absorbed or altered by digestive enzymes. erefore,
the beneĕcial clinical eﬀects are indirect. By binding the bile
acids, the drugs prevent the entry of bile acid into the blood
and thereby remove a large portion of the bile acids from the
enterohepatic circulation. e decrease in bile acid returned
to the liver leads to upregulation of key enzymes responsible
for bile acid synthesis from cholesterol. e increase in
cholesterol catabolism to bile acids results in a compensatory
increase in hepatic LDLR activity, clearing LDL-C from the
circulation and thus reducing LDL-C levels [20].ese agents
also reduce glucose levels in hyperglycemic patients [21–23];
however, the mechanisms behind this reduction are not fully
understood.
Compared with the ĕrst-generation bile acid sequestrants
(cholestyramine and colestipol), the second-generation bile
acid sequestrant colesevelam hydrochloride (HCl) exhibit
a greater binding capacity for bile acids. erapy with
colesevelam can lower LDL-cholesterol levels by 15–19%
[24, 25]; colesevelam can also be safely combined with statin
therapy in patientswhowould beneĕt fromadditional LDL-C
lowering, resulting in LDL-C reductions of 42–48% [26, 27].
No major eﬀect on HDL-C has been reported, while TG may
increase in some predisposed patients.
2.3. Cholesterol Absorption Inhibitors. Ezetimibe is a lipid-
lowering drug that inhibits intestinal uptake of dietary and
biliary cholesterol by binding to the Niemann-Pick C1-like
1 protein, a sterol transporter [28]. By inhibiting cholesterol
absorption at the level of the brush border of the intestine,
ezetimibe reduces the amount of lipoprotein cholesterol
circulated to the liver. In response to reduced cholesterol
delivery, the liver reacts by upregulating LDLR, which in
turn leads to increased clearance of LDL from the blood.
Ezetimibe reduces LDL-C in hypercholesterolemic patients
by 15–22% [29]; combined therapy with ezetimibe and a
statin provides an incremental reduction in LDL-C levels of
15–20% [30, 31]. Ezetimibe also decreases triglycerides by
up to 8% and raises HDL-C by 1–4%. e capacity of eze-
timibe/simvastatin to reduce risk for cardiovascular events
in patients with CAD is being studied in the IMPROVE-IT
trial [32]. Furthermore the SHARP trial [33] showed that
lipid-lowering therapy with ezetimibe in combination with
simvastatin is safe and signiĕcantly reduces the incidence
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T 1: Established pharmacological agents for dyslipidaemia management and their eﬀects on lipid fractions.
Agent Lipid fraction (%)
LDL-C HDL-C TG
Bile acid sequestrants 15–30↓ 3–5↑ No change
Ezetimibe 18–20↓ 1–4↑ 8↓
Statins 18–55↓ 5–15↑ 7–30↓
Fibrates 5–20↓ 10–20↑ 20–50↓
Nicotinic acid 5–25↓ 15–35↑ 20–50↓
Ezetimibe + statin +15–20↓ versus statin alone
Fibrate + statin +5↓ versus statin alone +5↑ versus statin alone
Nicotinic acid + statin +8–31↓ versus statin alone +17–32↑ versus statin alone +24–27↓ versus statin alone
of major atherosclerotic events in high-risk patients with
advanced chronic kidney disease.
Ezetimibe can be used as second-line therapy in associa-
tion with statins when the therapeutic target is not achieved
at maximal tolerated statin dose or in patients intolerant of
statins or with contraindications to these drugs.
2.4. Statins. Several clinical trials have demonstrated that
statins signiĕcantly reduce cardiovascular morbidity and
mortality in both primary and secondary prevention [34–
40]. Statins slow the progression or promote the regression
of coronary atherosclerosis; statin treatment signiĕcantly
reduces the carotid intima-media thickness (IMT), a surro-
gate marker of atherosclerosis [41].
Statins inhibit HMG-CoA reductase activity resulting
in the inhibition the conversion of acetyl-coenzyme A and
acetoacetyl-coenzyme A to mevalonate, a key step in choles-
terol synthesis. is inhibition leads to a reduced synthesis
of cholesterol in the liver and in an increased expression
of hepatic low-density lipoprotein receptor (LDLR), thus
reducing the concentration of circulating LDL-C and other
apoB-containing lipoproteins including TG-rich particles.
All statins induce modest elevations in HDL-C [42], with
diﬀerences among statins [43]. Current available evidence
suggests that the clinical beneĕt is largely independent of the
type of statin but depends on the extent of LDL-C lowering;
therefore, the type of statin used should reĘect the degree of
LDL-C reduction that is required to reach the target LDL-C
in a given patient [37].
Besides, statins exhibit several pleiotropic beneĕcial
eﬀects that are independent of cholesterol lowering properties
[44, 45].
(i) e inhibition of HMG-CoA reductase lead to
the inhibition of isoprenoid intermediates synthesis,
including farnesyl pyrophosphate (FPP) and ger-
anylgeranyl pyrophosphate (GPP). Isoprenylation of
proteins is involved in the activation of inĘammatory
pathways [46] and in the vascular remodeling present
in disease state such as atherosclerosis and diabetes
[47]; blocking thismetabolic pathway protects against
the progression of atherosclerosis.
(ii) Statins reduce platelet activation and aggregabil-
ity in both cholesterol-dependent and cholesterol-
independent manner [48, 49]. Furthermore, statins
decrease LDL-induced platelet aggregation [50, 51].
(iii) Statins reduce the proatherogenic eﬀects of OxLDL
by several ways, including the downregulation of
macrophage and endothelial scavenger receptors,
thus reducing the uptake of OxLDL [52–55].
(iv) Statins promote eNOS production and function in
endothelial cells by increasing eNOS expression and
activity, and by preventing the downregulation of
eNOS expression and activity induced by OxLDL
[56].
(v) Statins promote endothelial progenitor cell prolifera-
tion, migration, and cell survival [57–60].
(vi) Statins reduce vascular smooth muscle cell migration
and proliferation, two key steps of atherogenesis
process [61, 62], while promoting vsmc apoptosis
[63, 64].
(vii) Statins reduce the inĘammatory response by inhibit-
ing the induction of major histocompatibility com-
plex class II (MHC-II), involved in the activation of T
lymphocytes and in the control of immune response
[65] and by decreasing CD40 expression and function
in vascular cells [66].
(viii) Statins stabilize atherosclerotic plaque by lipid lower-
ing [67] and by decreasing the expression of matrix
metalloproteinases and tissue factor [68, 69].
(ix) Statins decreasemyocardial remodeling, by inhibiting
some eﬀects of angiotensin II (a major eﬀector of the
renin-angiotensin system), including cardiac ĕbrob-
last proliferation, collagen synthesis, and induction
of cardiomyocyte proliferation [70, 71], providing a
beneĕcial eﬀect for heart failure.
2.5. Fibrates. Increased triglyceride levels are key features
in certain conditions that lead to premature vascular dis-
ease, including type 2 diabetes mellitus, familial combined
hyperlipidaemia. and familial hypoalphalipoproteinaemia.
Elevated levels of TG are closely correlated with low HDL-
cholesterol levels.
4 Scientiĕca
Fibrates are agonists of peroxisome proliferator-activated
receptor-𝛼 (PPAR-𝛼); by interacting with PPAR-𝛼, ĕbrates
recruit diﬀerent cofactors and regulate the expression of
several genes involved in cholesterol transport and lipid
metabolism. As a consequence, ĕbrates enhance degradation
of triglyceride-rich particles by activation of lipoprotein
lipase and decrease hepatic very low density lipoprotein
production [72], resulting in a signiĕcant reduction of TG
levels (up to 50%); they induce the synthesis of apoA-I and
apoA-II, leading to a modest increase of HDL Cholesterol
levels (up to 10–15% in short-term studies and <5% in
the long-term intervention trials) [73], and promote a shi
in the LDL-C particle distribution towards larger, more
buoyant particles which are less susceptible to oxidation and
possess higher aﬃnity for the LDL receptor [74, 75]. Due
to their eﬀects, ĕbrates are commonly used in subjects with
signiĕcant hypertriglyceridaemia.
However, clinical trial data on the role of ĕbrates in
cardiovascular prevention are conĘicting. Fenoĕbrate did
not signiĕcantly reduce the risk of the primary outcome of
coronary events in the FIELD trial [76]. Total cardiovascular
events resulted decreased, due to reduced nonfatal myocar-
dial infarctions and revascularisations. Furthermore, a meta-
analysis of 10 randomized placebo-controlled trials revealed
that long-term therapy with ĕbrates signiĕcantly reduces
the occurrence of nonfatal myocardial infarction but has no
signiĕcant eﬀect on other adverse cardiovascular outcomes
[77]. Finally, the results of the ACCORD trial showed that the
combination of fenoĕbrate and simvastatin does not reduce
the risk of cardiovascular disease in patients with type 2
diabetes mellitus, as compared with statin monotherapy [78];
only subgroups of patients with dyslipidemia seem to beneĕt
from ĕbrate therapy. us, the overall eﬃcacy of ĕbrates on
cardiovascular outcomes is much less robust than that of
statins.
2.6. Omega-3 Fatty Acids. Omega-3 fatty acids [eicosapen-
taenoic acid (EPA) and docosahexaenoic acid (DHA)] are
components of ĕsh oil and the Mediterranean diet and
their use is beneĕcial for the cardiovascular system [79–
81]. Omega-3 fatty acids decrease serum levels of VLDL and
triglycerides by several mechanisms [82].
Clinical studies have shown the beneĕcial eﬀect of
omega-3 fatty acids.e GISSI Prevenzione trial showed that
the use of omega-3 fatty acids was associated to signiĕcant
reductions in the risk for reinfarction and sudden death
among patients who sustained an acute coronary syndrome
prior to randomization [83]; in another study, the addition of
EPA to statin therapy resulted in a 19% incremental reduction
in major coronary events compared with statin monotherapy
[84].
Not all trials have demonstrated a positive eﬀect of
omega-3 supplementation on cardiovascular disease [85, 86];
for example, low-dose supplementation with omega-3 fatty
acids did not reduce the incidence of major cardiovascular
events in patients who have had a myocardial infarction [87].
Clinical and mechanistical studies are required to deĕne
the beneĕts of omega-3 fatty acids in both primary and
secondary prevention.
2.7. Nicotinic Acid. Nicotinic acid has broad lipid-
modulating action, raising HDL-C in a dose-dependent
manner by ∼25%, and reducing both LDL-C by 15–18% and
TG by 20–40%. Nicotinic acid is unique in lowering Lp(a)
levels by up to 30% at this dose. It is therefore primarily
used in subjects with low HDL-C levels as typical of mixed
hyperlipidemia, HTG, or in FCH, but may also be used
in subjects with insulin resistance (type 2 diabetes and
metabolic syndrome). Nicotinic acid has multiple beneĕcial
eﬀects on serum lipids and lipoprotein. In fact, nicotinic
acid induces hepatic production of apoA-I and HDL [88];
furthermore it inhibits HDL particle uptake and catabolism
in the liver [89]. Nicotinic acid reduces hepatic VLDL andTG
secretion by several mechanisms. It decreases the Ęux of fatty
acid from adipose tissue to the liver (due to the inhibition
of hormone-sensitive lipase activity) [90]; it inhibits TG
formation in the liver (by inhibition of diacylglycerol
acyltransferase); it increases apoB catabolism, resulting in
VLDL-cholesterol and LDL-cholesterol reduction.
Nicotinic acid may be used in combination with statins
as a therapy for combined hyperlipidemia. Nicotinic acid is
currently used mostly as an extended release (ER) form. In
patients with established CHD, the addition of extended-
release (ER) niacin to statin therapy results in the stabilization
of CIMT, in contrast to patients receiving statinmonotherapy
who experienced signiĕcant CIMT progression, despite hav-
ing a mean baseline LDL-C of 90mg/dL on statin monother-
apy [91]. CIMT regression resulted highly correlated with the
degree of HDL-Cholesterol increase [92, 93].
Niacin usage is limited by cutaneous Ęushing, a both-
ersome adverse eﬀect. Flushing is the leading cause for
discontinuation of therapy, estimated at 25–40% or more
[94, 95]. Flushing is mediated by prostaglandin D2 (PGD2),
a potent vasodilator. PGD2 binds to DP1 receptors in the
skin. ER niacin is associated with a lower frequency, intensity,
and duration of Ęushing than immediate release niacin [96–
98]. Laropiprant is an antagonist of the DP1 receptor, inhibits
cutaneous Ęushing and signiĕcantly improves the tolerability
of niacin by over 50% [96, 97].
In a recently published trial, the addition of niacin to
statin therapy did not induce an incremental beneĕt in
patients with established cardiovascular disease, low levels of
HDL-C at baseline and levels of LDL-C at target (<80mg/dL)
[98].
3. Emerging Approaches for theManagement of
Dyslipidaemia
e key role of dyslipidaemias in determining cardiovascular
disease (CVD) has been proved beyond reasonable doubt;
and the discovery of statins has provided a very eﬀective
approach in reducing cardiovascular risk as documented by
the results obtained in clinical trials and in clinical practice.
Research however is clearly suggesting that other lipoprotein
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classes beyond low-density lipoprotein (LDL) play important
roles in determining cardiovascular risk and that the current
eﬃcacy of statins or other drugs comes short of providing
the beneĕt that could derive from a further reduction of LDL
cholesterol (LDL-C) in high-risk and very-high-risk patients.
For these reasons a number of new potential drugs are under
development in this area.
3.1. Interfering with Lipoprotein Synthesis: ApoB Silencing,
MTP Inhibitors. Hepatic biosynthesis of very-low-density
lipoprotein (VLDL) is dependent on two dominant proteins,
namely, apolipoprotein B (apoB) and microsomal triglyc-
eride (TG) transfer protein (MTP). ApoB is an obligatory
structural component of VLDL and requires progressive
lipidation, mediated by the resident endoplasmic reticulum
chaperone MTP, to maintain conformational integrity and
folding during the process of lipoprotein assembly. Interfer-
ing with this process is therefore an attractive approach for
reducing lipoprotein synthesis and decreasing plasma LDL-
C concentration.e possibility of targeting apoB during the
process of gene translation is under extensive investigation.
One approach to blockmRNA translation of a gene is through
the use of a single-strand antisense oligonucleotide (ASO)
that is complementary to themRNA. Following hybridization
to the mRNA, the ASO inhibits translation and splicing and
leads to degradation of the mRNA by RNase [99]. ASO
kinetics are characterized by a large and rapid distribution
to the liver following parenteral administration, thus making
this approach quite attractive for inhibiting mRNA aer
transcriptional processing.is results in a reduced synthesis
of proteins in the liver, such as apoB [100] (Figure 1).
Preclinical studies demonstrated that ASOs targeting apoB
are quite eﬀective inmice in reducing apoBmRNA liver levels
in a dose-response manner [101] followed by a reduction in
circulating LDL-C concentration, LDL particle number, cir-
culating TG, and lipoprotein(a) [Lp(a)], while chylomicrons,
which contain apoB-48, were spared, because of the high
distribution of ASOs to the liver.
Mipomersen is an ASO targeting apoB which leads to
a dose-dependent reduction in apoB and total cholesterol
[102] and was eﬀective in phase II and phase III clinical
studies in combination with statin therapy in individuals
with LDL-C 100–220mg/dL on a maximal tolerated statin
dose with or without ezetimibe, bile-acid sequestrant and/or
niacin and in patients with familial hypercholesterolaemia
[102] as well as in monotherapy in individuals with mild-
to-moderate hyperlipidaemia [103] and in high-risk statin-
intolerant patients [104]. Overall, mipomersen provided
signiĕcant further reduction in LDL-C (∼30%) and other
lipids when added to conventional lipid therapy. e most
common adverse eﬀects were injection-site reactions and Ęu-
like symptoms. Liver fat accumulation was also observed in
both phase II and phase III studies and is in line with the
mechanism of action of the drug.
MTP, found in the endoplasmic reticulum of hepatocytes
and enterocytes, mediates the formation of apoB-containing
lipoproteins in the liver and in the intestine [105]. Mutations
in the gene encoding MTP can cause abetalipoproteinemia,
a rare genetic disease characterized by an absence of apoB-
containing lipoproteins and severe malabsorption of fat
and fat-soluble vitamins [105]. e genetic defect under-
lying abetalipoproteinemia suggests that inhibiting MTP
may reduce circulating concentrations of cholesterol and
apoB-containing lipoproteins (Figure 1). e MTP inhibitor
lomitapide is currently in phase III testing. e drug, tested
in monotherapy or in combination with conventional lipid-
lowering therapy in homozygous FH [106] or in patients
with hypercholesterolaemia (LDL-C 130–250mg/dL) [107]
showed a reduction in circulating LDL-C, apoB, total choles-
terol, nonhigh-density lipoprotein cholesterol (non-HDL-C),
and Lp(a) levels. Steatorrhea related to lomitapide treatment
was eﬀectively reduced by a fat-restricted diet; adverse eﬀects
such as elevated liver enzymes and hepatic-fat accumulation
(expected from the mechanism of action) were reported and
may restrict the patient population for this drug. However,
for patients with homozygous FH that cannot be controlled
with conventional lipid-lowering therapy, MTP inhibition
may be a beneĕcial approach. Ongoing studies of lomitapide
should provide additional information on the safety and
tolerability of this agent and potential patient populations for
whom it may be appropriate.
3.2. Promoting LDL-Receptor Activity: PCSK9 Inhibitors.
Cholesterol homeostasis is regulated by the LDL receptor
(LDL-R) through its binding and uptake of circulating apoB-
containing lipoproteins which are then internalized into the
liver cell. e key mechanism associated with statins’ action
involves the increase of LDL-R expression on the hepatocyte
surface, followed by increased LDL turnover and reduction
of plasma cholesterol levels. is mechanism is partially
dampened by a negative feedback response associated with
the induction of the expression and secretion of proprotein
convertase subtilisin/kexin type 9 (PCSK9) [108], a serine
protease which promotes the degradation of LDL-R [109]
thus attenuating, at least in part, lipid-lowering eﬃcacy of
statins and ezetimibe [110].
Given that PCSK9 acts both intracellularly, as a chap-
erone directing the LDL-R to the lysosomes, and in the
circulation, by promoting LDL-R internalization [110], the
possibility of inhibiting PCSK9 represents a logical step
to enhance the lipid-lowering eﬀect of conventional agents
[110] (Figure 1). To this end, at least ĕve diﬀerent human
monoclonal antibodies and three gene-silencing approaches
are under development. Among a series of antibodies against
PCSK9, clinical trial results are available for two of them,
SAR236553/REGN727 [111] and AMG145 [112], and these
compounds are both in phase II or III development. A
number of additional anti-PCSK9 monoclonal antibodies,
in earlier clinical development, are currently being inves-
tigated for potential use in humans, including 1B20, PF-
04950615/RN-316, and LGT 209.
To date the largest body of information is available for
REGN727/SAR236553, a fully human monoclonal antibody,
which binds to the catalytic domain of PCSK9 that interacts
with LDL-R. Overall, results from phase I and II clinical trials
suggest that s.c. injections of SAR236553/REGN727 dose
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F 1: Emerging targets for dyslipidemia. e novel drugs that are under development for the treatment of dyslipidemia present several
mechanisms of action. Emerging therapeutic agents for LDL lowering will: (a) interfere with lipoprotein synthesis in the liver by silencing
apolipoprotein B (apoB) expression (1) or inhibiting microsomal triglyceride transfer protein (MTP) activity (2); (b) promote LDL-receptor
activity by silencing (3) or blocking (4) proprotein convertase subtilisin/kexin type 9 (PCSK9). Emerging therapeutic agents aﬀecting HDL
will: (c) increase HDL-C plasma levels by blocking cholesteryl ester transfer protein (CETP) (5), or inducing apolipoprotein A-I (apoA-
I) expression (6), (d) improve HDL activity by mimicking apoA-I (7) or nascent HDL (8) or increase the expression of receptors favoring
cholesterol eﬄux from cells (9). Emerging therapeutic agents for triglycerides lowering will improve the catabolism of triglycerides and
the handling fatty acids by peripheral organs (10), by new formulation of omega 3 fatty acids (11) and by inhibiting the expression of
apolipoprotein C-III in the liver (12). Speciĕc silencing of apolipoprotein (a) is also under investigation (13).
dependently reduce PCSK9 activity and produce signiĕcant
additional reductions in LDL-C as well as in non-HDL-C
independently of statin treatment. e antibody was gener-
ally well tolerated over the treatment period, with no drug-
related adverse eﬀects on liver function tests or other labora-
tory parameters, and no serious treatment-emergent adverse
eﬀects [111, 113, 114].e number of injection-site reactions
(including erythema, pruritis, swelling, haematoma, and
rash) was generally low and the few reported were mild in
severity [113].
AMG145 is another fully human monoclonal antibody
which also binds speciĕcally to human PCSK9. Phase I data
in subjects on stable statin therapy demonstrated a dose-
dependent decrease in LDL-C and unbound PCSK9 with
increasing subcutaneous doses of AMG145. LDL-C was low-
ered by up to 81% at maximal doses, over and above the LDL
lowering achieved with statin alone [112]. Phase I data [112]
indicated no serious adverse events in the AMG145 group
compared with placebo, no discontinuations from the studies
related to adverse events and only 1 case of transaminase
elevation >3× upper limit of normal. Although the safety
results for PCSK9 monoclonal antibodies are encouraging, it
should be noted that the trials to date have been relatively
short in duration and were conducted in relatively small
patient populations. Further trials are therefore required to
test the long-term safety and eﬃcacy of PCSK9 monoclonal
antibodies in larger and more varied patient populations.
In this context, given that statin treatment increases PCSK9
levels, it should be considered that the frequency of injection
should be increased accordingly in statin-treated patients for
optimal PCSK9 inhibition.
PCSK9 can also be suppressed through gene silencing;
among the nucleic acid-based therapies, the development of
SPC5001, a locked nucleic acid-based inhibitor, and that of
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BMS-844421, an antisense RNA therapy, were terminated
during phase I clinical trials. ALN-PCS02, an RNA interfer-
ence molecule, is being tested in an ongoing phase I study
in healthy volunteers to evaluate the safety and tolerability of
various doses. In interim data on 20 subjects, robust target
protein knockdown was observed at the highest dose tested,
with a mean 60% reduction in plasma PCSK9 levels 3–5 days
aer administration. In line with PCSK9 genetics, this type of
knockdown entailed a mean 39% reduction in LDL-C., with
no drug-related discontinuations or liver enzyme elevations
(http://www.clinicaltrials.gov/ct2/show/NCT01437059).
3.3. Increasing Plasma HDL-C Levels: CETP Inhibitors, ApoA-
I Inducers. High-density lipoproteins (HDL) possess several
physiological activities that may explain their antiatheroscle-
rotic properties; among them, the most relevant is the
ability of HDL to promote the eﬄux of excess cholesterol
from peripheral tissues to the liver for excretion [115, 116].
Furthermore, apolipoproteins, lipids, and enzymes carried
byHDLmay perform additional antiatherosclerotic activities
[117–119].
In recent years, the metabolic pathways associated with
HDL have been extensively investigated and elucidated,
allowing the design of drugs able to interfere with HDL
catabolism, improve the expression of the main protein
constituent, namely, apoA-I, or mimic their activity.
e pharmacological approaches under development can
be grouped in two major clusters: molecules increasing
plasma HDL levels and molecule improving HDL function.
It is expected that an increase in HDL levels can be beneĕcial
when associated with an improvement in HDL function.
Recently, a mendelian randomization analysis revealed
that a single nucleotide polymorphism in the endothelial
lipase gene (LIPG Asn396Ser) associated with increased
HDL-C levels in the population did not decrease the risk
of myocardial infarction, despite a 13% reduction expected
from the increased HDL-C levels [120]. Similarly, a genetic
score combining 14 variants exclusively related to HDL-C
was not associated with myocardial infarction risk [120],
further challenging the concept that higher HDL-C levels
will automatically translate into lower cardiovascular risk. In
spite of these observations, clinical trials are still ongoingwith
drugs aﬀecting HDL levels.
Cholesteryl ester transfer protein (CETP) is an enzyme
involved in the transfer of cholesteryl esters fromHDL toLDL
andVLDL; this process results in a reduction and remodeling
of HDL particles and in an increase of LDL and VLDL levels.
Furthermore, CETP transfers TG from VLDL or LDL to
HDL, resulting in the formation of TG-enriched HDL, which
is easily hydrolyzed by hepatic lipase leading to TG-rich small
HDL that are clearedmore rapidly from the circulation [121].
Under pathological conditions, including atherosclerosis,
CETP activity is increased; moreover, in humans, CETP
deĕciency results in increased HDL levels. Altogether these
observations led to the concept that CETP inhibition is
a powerful tool to increase HDL-C, decrease LDL-C and
VLDL-C, and reduce the development of atherosclerosis
[122].
e ĕrst CETP inhibitor developed, torcetrapib, despite
a 72% increase in HDL-C levels, was withdrawn because of
an increased risk of cardiovascular events and death from
any cause in the investigation of lipid levels management
to understand its impact in atherosclerotic events (ILLUMI-
NATE) trial [123]. Retrospectively, this eﬀect was attributed
to an oﬀ-target eﬀect of torcetrapib such as the rising of
systolic blood pressure by an average 5.4mmHg [124], an
eﬀect associated with the stimulation of aldosterone synthesis
via pathways independent of CETP inhibition [123, 125].
e possibility that CETP inhibition per se could generate
larger cholesterol-enriched HDL with impaired cholesterol
eﬄux potential was also proposed [124]. However this was
not conĕrmed by in vitro studies. Among the three newer
compounds, dalcetrapib, anacetrapib, and evacetrapib, with
diﬀerent potency toward CETP inhibition (evacetrapib >
anacetrapib > dalcetrapib) and apparently lacking the oﬀ-
target eﬀects of torcetrapib, two remain under development,
while that of dalcetrapib was recently halted.
e decision to stop dalcetrapib was based on the
dal-OUTCOMES trial interim analysis which showed that
dalcetrapib, in acute coronary syndrome patients, failed to
demonstrate a signiĕcant reduction in cardiovascular adverse
events (http://www.roche.com/media/media_releases/med-
cor-2012-05-07.htm). In contrast to the earlier CETP
inhibitor, torcetrapib, no safety concerns were reported. In
addition, the dal-VESSEL study showed that dalcetrapib
reduced CETP activity and increased HDL-C levels without
aﬀecting nitric oxide-dependent endothelial function, blood
pressure, or markers of inĘammation and oxidative stress
[126] while the dal-PLAQUE study demonstrated some
beneĕcial vascular eﬀects of the drug, including the reduction
in total vessel enlargement over 24 months [127].
While disappointing, the pursuit of an extensive pro-
gramme of clinical trials and basic research to develop
dalcetrapib has provided new information on the biology
of HDL in both man and animal models, and on CETP
inhibition as a viable therapeutic target for raising levels
of HDL-C. Several other CETP inhibitors that raise HDL-
C levels to a greater extent than dalcetrapib and also sig-
niĕcantly lower LDLC and other novel HDL-raising agents
remain under development. Ultimately, the beneĕts of each
of these novel CETP inhibitors must be determined through
prospective, randomized, clinical outcome trials. e pos-
sibility that, while CETP inhibitors were developed on the
premise that they would increase HDL-C more than any
therapy currently available, the beneĕt may still be largely
due to the incremental lowering of LDL-C observed with the
more potent inhibitors, should be considered for the transfer
of these drugs in the clinical practice.
e life cycle of HDL starts from lipid-poor apoA-I,
termed nascent, or pre𝛽-HDL (the latter on the basis of
the characteristic electrophoretic mobility), which promotes
cholesterol mobilization from the cell membrane mainly
through the activation of ABCA-1. Pre-𝛽 HDL accumulates
eﬄuxed cholesterol and matures to 𝛼 HDL, which further
promotes cholesterol eﬄux via the activation of diﬀerent
transporters including ATP-binding cassette subfamily G
member 1 protein (ABCG-1) and scavenger receptor class B
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member 1 (SR-BI) (Figure 1). Induction of the expression of
apoA-I is therefore a cornerstone mechanism of drugs so far
used to increase HDL levels, including ĕbrates and nicotinic
acid [88]. A novel small synthetic molecule, RVX-208, is
able to induce apoA-I synthesis and is under development.
Preclinical studies in nonhuman primates showed the ability
of this compound to increase plasma apoA-I and HDL-C
levels by up to 60% and 97%, respectively. In humans, the
ASSERT study showed that the administration of RVX-208 at
a dose of 50, 100, or 150mg twice daily for 12 weeks resulted
in increases in apoA-I (up to 5.6%), HDL-C (by 3.2% to
8.3%), and large HDL particles (by 11.1% to 21.1%), although
the primary endpoint of individual pairwise comparisons of
apoA-I changes with placebo was not statistically signiĕcant
[128]. ese ĕndings, although not at the level expected,
require further evaluation, perhaps through the investigation
of HDL functionality.
3.4. Improving HDL Activity. e rationale behind the devel-
opment of HDL mimetics is the possibility of mimicking the
ĕrst phase of the HDL life cycle and promoting cholesterol
eﬄux, mainly from cholesterol-loaded cells in the vascular
wall such as macrophages and foam cells (Figure 1).
To this aim, lipid-poor apoA-I-phospholipid complexes
have been extensively studied in preclinical models and
preliminary studies in humans. So far, diﬀerent approaches
are under investigation. CSL-111 is a complex of native apoA-
I and phosphatidylcholine isolated from soybeans which
induced a signiĕcant reduction in atheroma volume com-
pared with baseline [129]. e same study showed signiĕ-
cantly reduced progression of coronary atherosclerosis in the
CSL-111–treated group compared to placebo. Treatmentwith
CSL-111, however, induced reversible alanine aminotrans-
ferase elevations exceeding 10 times the normal upper limit in
one-third of patients receiving 80mg of the compound, while
no changes were observed in patients receiving 40mg/kg
[129]. To overcome this limitation, a reformulated version,
CSL-112, with greater cholesterol eﬄux capacity and less
hepatotoxicity, is in phase I study.
A similar approach was tested also by incorporating
recombinant apoA-I Milano, which diﬀers from normal
apoA-I by a cysteine-to-arginine substitution at amino acid
173. ETC-216 is a complex of apoA-I Milano with phospho-
lipid and in a small clinical study signiĕcantly reduced total
atheroma volume, measured by IVUS, in patients with acute
coronary syndrome [130]. Since 2003, ETC-216 development
was halted and only recently a diﬀerent company bought the
license and renamed the molecule MDCO-216 with the aim
of starting larger clinical trials soon.
CER-001, a synthetic recombinant human apoA-I
HDL mimetic, is in phase II testing in approximately
500 patients with acute coronary syndrome, to
determine the eﬀect on atherosclerotic plaque
progression/regression as assessed by IVUS (CHI SQUARE;
http://clinicaltrials.gov/ct2/show/NCT01201837). Several
other complexes of apoA-I and diﬀerent phospholipids are in
preclinical development and will soon enter clinical testing
phases.
A second approach to improve HDL function is repre-
sented by small peptides design to mimic apoA-I function.
e most well-studied of these peptides is 4F, consisting of
18 amino acids, which was designed to have the lipid-binding
properties of apoA-I through a common secondary structure,
the class A amphipathic helix. e use of D-amino acids (D-
4F) enables oral delivery of this compound by conferring
resistance to gastrointestinal proteolytic enzymes. Several
preclinical studies showed that 4F promotes cholesterol eﬄux
via ABCA1 and SR-BI, and possesses anti-inĘammatory,
antithrombotic and antioxidant properties.e only available
human study of D-4F showed that HDL isolated from
subjects treated with a single 300mg or 500mg dose of
unformulatedD-4F had increased inhibition of LDL-induced
monocyte chemotaxis compared to HDL isolated from con-
trol subjects. Data on the safety proĕle of D-4F in humans
are not available yet. Overall at least 22 apoA-I mimetics are
under development [131]; however, with the exception of D-
4F, the other peptides require parenteral administration and,
in humans, data on eﬃcacy, tolerability, and safety, including
autoantibody generation, are lacking.
3.5. Dual PPAR Agonists. PPAR-𝛼 is highly expressed in liver
and skeletal muscle, controls the genes involved in fatty acid
oxidation, and plays a pivotal role in energy homeostasis and
lipoprotein metabolism by inducing lipoprotein lipase and
apoA-I expression. PPAR-𝛾 is highly expressed in adipocytes,
in addition to skeletal muscle, liver, and kidney, and has
been shown to regulate the expression of genes that mediate
adipocyte diﬀerentiation, energy metabolism, and insulin
action. erefore, a dual PPAR-𝛼 and -𝛾 agonist may pos-
sess the beneĕcial eﬀects of ĕbrates (PPAR-𝛼 agonists) on
plasma lipids and thiazolidinediones (PPAR-𝛾 agonists) on
insulin sensitivity and potential anti-inĘammatory eﬀects.
is approach could prove beneĕcial in eﬀectively managing
both glycaemic control and lipid proĕle particularly in
patients with type 2 diabetes.
Several attempts to develop a dual PPAR agonist for
diabetes have so far failed because of various safety concerns:
ragaglitazar, MK-0767, and naveglitazar were found to be
associated with an increased incidence of bladder cancer and
hyperplasia in rodent studies and tesaglitazar development
was discontinued because of indications that it may cause
kidney dysfunction.
e dual agonist muraglitazar, a strong PPAR-𝛾 ago-
nist with moderate PPAR-𝛼 eﬀects, eﬀectively reduced
haemoglobin A1c (HbA1c) and TG levels while increasing
HDL-C levels [132]. e development of muraglitazar was
stopped because of an excess incidence of the composite end
point of death, major adverse cardiovascular events (myocar-
dial infarction, stroke, and transient ischaemic attack), and
congestive heart failure compared to placebo [133].
e latest dual PPAR-𝛼/𝛾 agonist in development is alegli-
tazar, which is currently in phase III trials. is compound
has a balanced aﬃnity for both𝛼 and 𝛾 receptor subtypes.e
phase II study SYNCHRONY has shown a signiĕcant dose-
dependent reduction inHbA1c, in fasting plasma glucose, TG
andLDL-C, and an increase inHDL-C [134]. Further analysis
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of this study indicated that aleglitazar produced a shi from
atherogenic small dense LDL particles associated with type 2
diabetes to larger LDL particles.
is broad range of lipid improvements with aleglitazar
addresses the pattern of dyslipidaemia oen found in patients
with type 2 diabetes.is agent may therefore have beneĕcial
cardiovascular as well as anti-inĘammatory eﬀects, and long-
term use may delay the progression of CVD. Adverse events
with aleglitazar were mild (increases in body weight, the
number of patients with oedema) and no indications of CVD
or hepatotoxicity with this dual agonist was observed.
Whether these beneĕts will result in a reduction of
cardiovascular events is under evaluation in the large phase
III study ALECARDIO. is study will also address the
safety and tolerability of aleglitazar with a special focus on
common PPAR-𝛾-related side eﬀects such as weight gain,
Ęuid retention, and bone fractures.
3.6. New Omega-3 Fatty Acid Formulations. Two new
formulations of omega-3 fatty acids may provide
additional TG-lowering eﬀects by reducing VLDL
production and increasing their catabolism. AMR101,
which contains ≥96% eicosapentaenoic acid (EPA),
ethyl ester, and no docosahexaenoic acid (DHA),
reduced TG (relative to placebo, at 4-g/day dose) by
33% in patients with hypertriglyceridaemia [135] and
by 21.5% in patients with mixed dyslipidaemia also
receiving statin [136], signiĕcantly reduced non-HDL-
C, apoB and VLDL-C and did not increase LDL-C
[135, 136]. e ongoing reduction of cardiovascular
Events with EPA-Intervention Trial (REDUCE-IT) is
a cardiovascular outcomes study of AMR101 4 g/day
in approximately 8000 patients at high risk for CVD
events (http://clinicaltrials.gov/ct2/show/NCT01492361).
Another new omega-3 fatty acid formulation, an
ultrapure mixture of free fatty acid forms of EPA
and DHA that also provides better absorption than
traditional omega-3 preparations, is in phase III clinical
trials in patients with hypertriglyceridaemia (EVOLVE;
http://clinicaltrials.gov/ct2/show/NCT01242527) and added
onto statin therapy in patients with mixed dyslipidaemia
(ESPRIT; http://clinicaltrials.gov/ct2/show/NCT01408303).
3.7. Lipoprotein (a) Lowering Drugs. Lp(a) has been consid-
ered a cardiovascular risk factor for a long time and during
the last few years, major advances have been achieved in
understanding the causal role of elevated Lp(a) in premature
CVD [137]. Although the beneĕts of lowering Lp(a) per
se are still not demonstrated, a number of clinical and
experimental studies, including mendelian randomization
studies, indicate that this lipoprotein is causal in CVD [138,
139]. Whether this occurs by proatherogenic mechanisms,
enhancing coagulation, or both remains to be addressed.
Compared with LDL, Lp(a) is relatively refractory to both
lifestyle and drug intervention. e data on the eﬀects of
statins and ĕbrates on Lp(a) are limited and highly variable.
Overall, statins have, however, been shown to consistently
and modestly decrease elevated Lp(a) in patients with het-
erozygous familial hypercholesterolaemia. Niacin reduces
Lp(a) levels by up to 40% in a dose-dependent manner and
in addition exerts other potential beneĕcial eﬀects by reduc-
ing LDL-C, total cholesterol, TG, and remnant cholesterol
and by raising HDL-C [137]. Niacin (1–3 g/day) reduces
major coronary events, stroke, and any cardiovascular event
by 25–27%. However, controlled-intervention trials with
selective reduction in plasma Lp(a) levels aimed to reduce
CVD are urgently needed; selective Lp(a) apheresis may
represent such an approach [137]. Other agents reported
to decrease Lp(a) to a minor degree (10%) include aspirin,
L-carnitine, ascorbic acid combined with L-lysine, cal-
cium antagonists, angiotensin-converting enzyme inhibitors,
androgens, oestrogen and its replacements (e.g., tibolone),
and antiestrogens (e.g., tamoxifen), while the development of
a thyroxine derivative such as eprotirome, although eﬀective
in reducing Lp(a), was halted because of long-term cartilage
damage in preclinical studies. e ongoing HPS2-THRIVE
trials and the data on the Lp(a) from AIMHIGH will provide
further information, although the niacin employed in these
trials is not selective for Lp(a) lowering as noted above.
More recently early preclinical studies suggest that target-
ing liver expression of apo(a) with ASOs directed to KIV-
2 repeats—which are expressed in multiple copies in the
human apo(a) gene—may provide a highly eﬀective approach
to lower elevated Lp(a) levels in humans.e development of
suchASOs to lower Lp(a) levelsmight then allow clinical tests
of the importance of lowering Lp(a) levels for the therapy and
prevention of CVD.
It is clear that more detailed studies of the metabolism
of Lp(a) are required to aid in the design and development
of selective and potent therapies for lowering Lp(a) [137].
Given the critical role of Lp(a) synthesis in determining the
plasma concentration of Lp(a), targeting either the synthesis
of apo(a) and/or the formation of Lp(a) would appear worth-
while. ASOs, PCSK9 inhibitors, apoB synthesis inhibitors,
and CETP inhibitors all aﬀect Lp(a) plasma levels and may
hold promise for the future.
4. Conclusion
Although statins provide eﬀective and substantial reductions
in LDL-C, non-HDL-C, and apoB, as well as other drugs
provide beneĕcial eﬀects on other lipids and lipoproteins,
many patients do not achieve the recommended goals despite
maximal therapy, and some patients cannot tolerate high-
dose statin therapy. Available agents combined with statins
can provide additional beneĕt on LDL-C reduction, and
agents in development may increase therapeutic options.
Genetic insights into mechanisms underlying regulation
of LDL-C levels have expanded potential targets of drug
therapy and led to the development of novel agents that
are still undergoing testing to determine eﬃcacy and safety.
Alternative targets such as triglycerides, HDL, and Lp(a)
also require attention; however, the available data are still
not conclusive. Drugs increasing HDL may not be all alike
and require adequate scrutiny of the mechanisms involved.
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Drugs increasing apoA-I availability may represent the best
approach. Lp(a) also represents an attractive target; however,
it will be diﬃcult to address, with currently available inter-
vention, whether decreasing Lp(a) provides a reduction in
cardiovascular risk. e most promising approaches such as
apoB synthesis inhibitors or PCSK9 inhibitors all decrease
LDL as well. Until we have a better understanding of these
issues, further LDL lowering in high-risk and very-high-risk
individuals is the most sound clinical approach.
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